Trevi Therapeutics (NASDAQ:TRVI) Price Target Raised to $20.00 at Oppenheimer

Trevi Therapeutics (NASDAQ:TRVI) had its price target increased by Oppenheimer from $12.00 to $20.00 in a research note published on Tuesday,Benzinga reports. The brokerage currently has an outperform rating on the stock.

Other research analysts have also recently issued research reports about the company. HC Wainwright increased their price objective on Trevi Therapeutics from $7.50 to $12.50 and gave the stock a “buy” rating in a research note on Monday. D. Boral Capital reissued a “buy” rating and issued a $21.00 price objective on shares of Trevi Therapeutics in a research note on Friday, March 7th. Needham & Company LLC increased their target price on Trevi Therapeutics from $8.00 to $25.00 and gave the company a “buy” rating in a research report on Monday. Finally, Raymond James raised Trevi Therapeutics from an “outperform” rating to a “strong-buy” rating and increased their target price for the company from $9.00 to $29.00 in a research report on Monday. Seven equities research analysts have rated the stock with a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $15.94.

Trevi Therapeutics Stock Up 3.8 %

Shares of NASDAQ:TRVI opened at $6.30 on Tuesday. Trevi Therapeutics has a 52-week low of $2.30 and a 52-week high of $7.39. The stock has a market cap of $484.26 million, a P/E ratio of -14.32 and a beta of 0.90. The business’s 50 day moving average is $4.22 and its 200 day moving average is $3.56.

Institutional Trading of Trevi Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Frazier Life Sciences Management L.P. lifted its holdings in shares of Trevi Therapeutics by 44.5% during the 4th quarter. Frazier Life Sciences Management L.P. now owns 10,664,774 shares of the company’s stock valued at $43,939,000 after purchasing an additional 3,283,684 shares during the last quarter. Point72 Asset Management L.P. purchased a new stake in shares of Trevi Therapeutics during the 4th quarter valued at $17,099,000. Vivo Capital LLC lifted its holdings in shares of Trevi Therapeutics by 116.3% during the 4th quarter. Vivo Capital LLC now owns 3,487,903 shares of the company’s stock valued at $14,370,000 after purchasing an additional 1,875,000 shares during the last quarter. Woodline Partners LP lifted its holdings in shares of Trevi Therapeutics by 429.9% during the 4th quarter. Woodline Partners LP now owns 3,212,597 shares of the company’s stock valued at $13,236,000 after purchasing an additional 2,606,370 shares during the last quarter. Finally, MPM Bioimpact LLC lifted its holdings in shares of Trevi Therapeutics by 101.2% during the 4th quarter. MPM Bioimpact LLC now owns 3,094,896 shares of the company’s stock valued at $12,751,000 after purchasing an additional 1,556,379 shares during the last quarter. Hedge funds and other institutional investors own 95.76% of the company’s stock.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.